BioNTech SE

BioNTech staged a strong single-session rally during regular trading hours, reaching $97.57 as of ET 09:58, up 3.89% from the previous close. The move was driven by pre-market buying momentum, with the stock opening with a gap at $94.53 and climbing steadily. Despite a weak Q1 2026 earnings report—revenue falling 31.6% YoY to $135.3 million and net loss widening to $609.6 million (EPS -$2.41)—the stock was supported by the recent announcement of a $1 billion ADS buyback plan and positive clinical data from the ASCO annual meeting on its late-stage oncology pipeline, alongside a Buy rating from Jefferies. The price has now decisively broken above both the 60-day MA ($94.41) and the 20-day MA ($90.52), yet remains 21.23% below its 52-week high of $124. However, after-hours trading saw the stock ease back to $93.92, suggesting some profit-taking.